DEFINING IMPACT OF HDAC INHIBITORS ON TUMOR IMMUNOGENICITY, T-CELL FUNCTIONALITY, AND PD-1 BLOCKADE RESPONSE IN NSCLC PATIENTS

H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc.

Investigators